Takeda’s epilepsy drug misses the mark in two Phase III trials
Takeda said that there are some positive signs in secondary endpoints and plans to discuss the next steps with the authorities.
18 June 2024
18 June 2024
Takeda said that there are some positive signs in secondary endpoints and plans to discuss the next steps with the authorities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.